Skip to content
Zydus Wellness logo

Zydus Wellness

ZYDUSWELL NSE
₹488.80 −4.55 (−0.92%)
P/E
82.57
View as Markdown
MCP
Close 4 Nov 2026 ₹488.80 +45.00 +10.1% 1Y
Start ₹443.80

Key Fundamentals

SmallcapFood ProductsFMCG

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
4.91%
Debt to Equity
0.55
EPS (TTM)
₹5.92
Book Value
₹185.68
Market Cap
—
P/E (TTM)
82.57
P/B
2.63
ROE
3.98%
Dividend Yield
0.24%
EBITDA
₹516 Cr
52W High
₹611.85
52W Low
₹367.55
Day Range
₹485.30 – ₹499.90
Volume
1,42,028

Peer Comparison

Fast Moving Consumer Goods › Food Products › Packaged Foods

Zydus Wellness peer comparison
Nestle
₹1,248.0058.21₹2,42,042 Cr41.661.12%73.20%84.10%₹25,581 Cr₹4,134 Cr
Britannia Industries
₹4,946.3045.75₹1,19,473 Cr23.331.84%53.50%56.00%₹19,529 Cr₹2,610 Cr
Zydus Wellness (this company)
₹488.8082.57₹15,590 Cr2.630.24%3.98%4.91%₹4,537 Cr₹188 Cr
Bikaji Foods International
₹472.9043.79₹11,876 Cr7.380.27%17.80%22.00%₹2,872 Cr₹272 Cr
Bombay Burmah Trading
₹1,274.206.89₹8,824 Cr1.261.36%18.70%33.00%₹19,915 Cr₹2,585 Cr
Mrs. Bectors Food
₹208.1643.01₹6,436 Cr5.030.62%11.40%14.10%₹2,119 Cr₹149 Cr
Gopal Snacks
₹246.8836.68₹3,136 Cr5.730.20%4.72%11.70%₹1,608 Cr₹84 Cr
Median 7 companies₹488.8043.79₹11,876 Cr5.730.62%17.80%22.00%₹4,537 Cr₹272 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

51 Average

Data confidence 100/100

Category scores

Quality
53
Average
Returns, margins, earnings quality 22% weight
Valuation
29
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
38
Weak
Solvency, leverage, coverage 9% weight
Momentum
52
Average
Trend strength, vol-adjusted 12% weight
Ownership
56
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 2.69 times its book value
  • Company has a low return on equity of 5.08% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 14.1% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1054
OscillatorsNeutral252
Moving AveragesStrong Bearish802

Key readings

RSI (14)
48.07
Neutral
MACD (12,26,9)
−9.48
Bullish
SMA (50)
513.63
Bearish
SMA (200)
491.85
Bearish

As of

Analyst Rating

Based on 7 analysts
BUY71%

5 of 7 analysts rate Buy, 2 Hold, 0 Sell.

As of

BUY
5
71%
HOLD
2
29%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+25.86%
5Y+16.23%
3Y+20.66%
1Y+46.22%
TTM+66.25%

Net profit

Net profit growth by window
10Y+6.49%
5Y+10.61%
3Y−14.03%
1Y−43.23%
TTM−42.51%

Operating cash flow

Operating cash flow growth by window
10Y+9.64%
5Y−4.67%
3Y+34.93%
1Y−40.53%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−10.04 pp
5Y−5.55 pp
3Y−2.06 pp
1Y−1.15 pp
TTM−0.82 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹431 Cr
Mar 2018₹513 Cr
Mar 2019₹843 Cr
Mar 2020₹1,767 Cr
Mar 2021₹1,867 Cr
Mar 2022₹2,009 Cr
Mar 2023₹2,255 Cr
Mar 2024₹2,328 Cr
Mar 2025₹2,709 Cr
Mar 2026₹3,961 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹111 Cr
Mar 2018₹137 Cr
Mar 2019₹171 Cr
Mar 2020₹142 Cr
Mar 2021₹119 Cr
Mar 2022₹309 Cr
Mar 2023₹310 Cr
Mar 2024₹267 Cr
Mar 2025₹347 Cr
Mar 2026₹197 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹117 Cr +32.6% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 29 Oct 2026
AI opinion · based on fundamentals
Risk high

Zydus Wellness Ltd trades at ₹479.5 as of 2026-10-29 with a market cap of ₹15,255.81 Cr. The company shows strong TTM sales growth of 66% but TTM profit has declined 31%, resulting in an elevated PE of 81x and a subdued ROE of 3.38%. The stock sits roughly 22% below its 52-week high of ₹611.85 while being about 30% above its 52-week low of ₹367.55.

Bull Case 7
  • TTM compounded sales growth stands at 66%, indicating a sharp acceleration in top-line revenue and potential market share gains in the food products segment.
  • 3-year compounded sales CAGR of 21% and 5-year CAGR of 16% demonstrate consistent medium-term revenue expansion well above the broader FMCG sector average.
  • 10-year compounded sales CAGR of 26% reflects a long track record of sustained revenue scaling, partly aided by inorganic growth.
  • The stock is up ~30% from its 52-week low of ₹367.55, showing renewed investor interest and price recovery momentum.
  • 3-year stock CAGR of 16% has rewarded patient shareholders despite near-term profit headwinds.
  • Debt-to-equity ratio of 0.55 remains manageable for a consumer goods company, suggesting the balance sheet is not over-leveraged.
  • The company is expected to deliver a good upcoming quarter, which could act as a near-term catalyst for re-rating if profit growth reverts.
Bear Case 7
  • TTM compounded profit has declined 31%, a sharp deterioration that signals significant margin compression or one-off cost pressures despite strong sales growth.
  • ROE of 3.38% (and a 3-year average of only ~5%) is well below the cost of equity, indicating the company is not generating adequate returns on shareholder capital.
  • ROCE of 3.43% is similarly weak, suggesting poor capital allocation efficiency across both equity and debt-funded assets.
  • Dividend yield of just 0.25% and a payout ratio of only 14.1% over three years offer negligible income to shareholders.
  • 5-year compounded profit CAGR of -2% shows that profitability has actually eroded over a half-decade horizon even as sales grew at 16% CAGR, pointing to structural margin challenges.
  • The stock trades at 2.62x book value (PB) despite sub-par return ratios, suggesting the market may be pricing in growth that has not yet translated to bottom-line performance.
  • Potential capitalisation of interest costs, if confirmed, could mean reported profits and asset values are overstated, masking the true debt-servicing burden.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Zydus Wellness delivered a strong Q2FY27 with consolidated sales up 74.6% and EBITDA up 271.7% YoY, returning to net profitability at ₹51 million. ESG credentials are solid with a leader-category rating of 72. The FSSAI label-claim notice is a minor regulatory risk to monitor, though the company has responded and asserts compliance. The earnings momentum is clearly improving, and sustaining top-line growth while expanding margins will be key to watch in H2FY27.

Headwinds 1
  • FSSAI notice on label claims Oct 23

    Zydus Wellness received an FSSAI notice on Sep 24 regarding product-label claims. The company responded on Oct 4, asserting claims are scientifically substantiated, but regulatory scrutiny remains a watch item.

Positives 3
  • Q2FY27 EBITDA surges 271.7% YoY Nov 3

    Consolidated EBITDA rose 271.7% YoY to ₹855 million in Q2FY27, and net profit turned positive at ₹51 million. Consolidated net sales jumped 74.6% YoY to ₹11,227 million.

  • Standalone profit up 53% YoY Nov 3

    Standalone revenue grew 7% YoY to ₹1,668 million in Q2FY27, with standalone net profit rising 53% YoY.

  • ESG leader rating of 72 Oct 16

    Zydus Wellness received an overall ESG score of 72 for FY26, placing it in the 'leader' category under NSE Sustainability Ratings.

Neutral 1
  • Q2FY27 investor call available Nov 3

    Audio recording of the Q2FY27 earnings investor call has been made available on the company website for stakeholder reference.

Quarterly Results

₹ Cr
ZYDUSWELL quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
702
440
403
783
841
493
462
913
861
650
965
1,485
1,437
1,127
Expenses
586
423
390
620
686
473
447
723
705
628
904
1,215
1,195
1,041
Operating Profit
116
17
13
162
155
20
15
190
156
23
61
270
242
—
OPM %
17%
3.8%
3.1%
21%
18%
4%
3.2%
21%
18%
3.5%
6%
18%
17%
—
Other Income
−12
4
3
4
5
10
4
1
3
−33
−6
1
4
6
Interest
5
6
6
6
4
1
3
4
2
16
41
39
26
27
Depreciation
6
6
6
6
5
5
5
13
11
25
56
55
57
57
PBT
93
9
4
154
152
24
10
173
145
−51
−42
177
162
8
Tax %
−18%
31%
92%
3%
3%
12%
37%
1%
12%
4%
−4%
9%
27%
33%
Net Profit
110
6
0
150
148
21
6
172
128
−53
−40
162
119
5
EPS (₹)
3.47
0.19
0.01
4.72
4.64
0.66
0.2
5.4
4.02
−1.66
−1.25
5.09
3.74
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
ZYDUSWELL profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
431
397
431
513
843
1,767
1,867
2,009
2,255
2,328
2,709
3,961
4,537
Expenses
331
305
331
387
658
1,446
1,522
1,664
1,918
2,020
2,329
3,451
3,941
Operating Profit
100
91
99
125
185
321
344
345
337
308
380
510
596
OPM %
23%
23%
23%
24%
22%
18%
18%
17%
15%
13%
14%
13%
13%
Other Income
28
32
32
35
28
−33
−123
10
−5
0
20
−34
−34
Interest
0
0
1
2
30
140
84
26
16
24
12
98
122
Depreciation
8
7
7
9
13
26
25
24
25
24
28
147
193
PBT
120
117
124
150
171
121
112
306
291
260
359
230
247
Tax %
7%
10%
10%
9%
0%
−17%
−6%
−1%
−7%
−3%
3%
14%
—
Net Profit
111
105
111
137
171
142
119
309
310
267
347
197
188
EPS (₹)
5.58
5.28
5.58
6.85
5.87
4.92
3.73
9.71
9.75
8.39
10.9
6.2
5.92
Div. Payout %
22%
25%
23%
23%
17%
20%
27%
10%
10%
12%
11%
19%
—

Balance Sheet

₹ Cr
ZYDUSWELL balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
39
39
39
39
58
58
64
64
64
64
64
64
Reserves
367
439
518
652
3,329
3,403
4,504
4,780
5,059
5,294
5,608
5,762
Borrowings
0
0
25
25
1,569
1,519
550
387
297
329
188
3,203
Other Liabilities
102
89
100
112
503
610
548
461
413
462
582
1,161
Total Liabilities
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,190
Fixed Assets
84
82
103
104
4,567
4,674
4,667
4,710
4,732
4,708
5,125
8,596
CWIP
0
0
0
0
10
4
4
12
13
10
15
23
Investments
0
94
30
148
46
110
0
27
70
78
36
5
Other Assets
423
391
550
577
835
802
995
943
1,018
1,354
1,266
1,566
Total Assets
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,190

Cash Flow

₹ Cr
ZYDUSWELL cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
69
90
77
69
149
259
287
237
92
246
380
226
Investing
29
−28
−72
−59
−4,092
−17
−10
−59
−85
−178
−207
−2,881
Financing
−27
−58
−6
−2
4,052
−260
−216
−234
−138
−26
−186
2,698
Net Cash Flow
71
4
−1
8
109
−18
60
−56
−132
43
−13
44
Free Cash Flow
72
86
46
61
132
235
269
162
47
220
315
126
CFO/OP
80
114
86
64
115
81
83
70
28
81
99
50

Ratios

ZYDUSWELL financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
1
3
3
6
42
24
18
26
34
44
49
35
Inventory Days
76
73
127
113
393
168
158
135
146
150
148
178
Days Payable
146
191
264
254
662
289
189
136
100
116
122
107
Cash Conversion Cycle
−69
−116
−134
−135
−227
−97
−13
25
80
78
75
106
Working Capital Days
−37
−38
−57
−26
−26
−7
−35
−27
17
20
34
48
ROCE %
32%
26%
23%
22%
7%
6%
6%
6%
6%
5%
6%
5%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Wellness insights

77 extracted metrics across FY09–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 69.64%
  • DIIs 19.39%
  • Public 5.73%
  • FIIs 3.56%
  • Others 1.67%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Zydus Wellness

What does Zydus Wellness Ltd do?
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.
Where is Zydus Wellness Ltd (ZYDUSWELL) listed?
Zydus Wellness Ltd trades as ZYDUSWELL on the NSE and under code 531335 on the BSE.
Which sector does Zydus Wellness Ltd belong to?
Zydus Wellness Ltd is classified under the Food Products sector, in the Packaged Foods industry.
What is the PE ratio of Zydus Wellness Ltd?
Zydus Wellness Ltd trades at a PE ratio of 82.57 as of 4 Nov 2026, on earnings per share of ₹5.92, against a book value of ₹185.68 per share.
What is the 52-week high and low of Zydus Wellness Ltd?
Over the last 52 weeks Zydus Wellness Ltd has traded between ₹367.55 and ₹611.85 as of 4 Nov 2026.
Does Zydus Wellness Ltd pay dividends?
Zydus Wellness Ltd has a dividend yield of 0.24%.
What is the Return on Equity (ROE) of Zydus Wellness Ltd?
Zydus Wellness Ltd reported a return on equity of 3.98%. Its debt-to-equity ratio is 0.55.

Company Information

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.

Website zyduswellness.com
CEO Mr. Tarun G. Arora
Employees 1,247
Listed 13 Nov 2009
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSWELL.md for Zydus Wellness Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Food Processing stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month